programmed cell death 7Genealiases: 59K · ES18 · HES18
Q-omics provides the consensus-scored PDCD7 profile across patient tissues and cancer cell-line models. PDCD7 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PDCD7 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, PDCD7 RNA expression shows 20,862 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, LIHC, and ACC as cancer lineages where PDCD7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDCD7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDCD7 survival associations across molecular data types. PDCD7 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDCD7 RNA expression–survival associations across cancer types. High PDCD7 expression shows unfavorable associations in KIRP, KICH, LIHC, UVM, ACC and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PDCD7 RNA expression.
This table summarizes PDCD7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in LIHC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PDCD7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDCD7 shows lower tumor expression in THCA and higher tumor expression in LIHC, COAD, KIRC, HNSC and LUSC. The LIHC box plot shows higher PDCD7 RNA expression in tumor versus normal tissue (log2 FC = +0.853, t-test p < 0.001).
This table shows molecular features associated with PDCD7 in patient tissues and cancer cell lines. In patient samples, PDCD7 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PDCD7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
